Title |
Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
|
---|---|
Published in |
OncoTargets and therapy, March 2013
|
DOI | 10.2147/ott.s32200 |
Pubmed ID | |
Authors |
Rajeev Rajendra, Robin L Jones, Seth M Pollack |
Abstract |
Soft tissue sarcomas comprise approximately 1% of all adult solid malignancies. While chemotherapy is the mainstay of treatment for patients with metastatic or inoperable disease, overall survival for these patients is approximately 12 months, highlighting the need for novel agents. Both laboratory and clinical data have suggested that antiangiogenic agents may have a role in the treatment of soft tissue sarcomas. Pazopanib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenic activity. The randomized, double-blind, placebo-controlled, Phase III PALETTE (pazopanib for metastatic soft-tissue sarcoma) study demonstrated improved progression-free survival in patients receiving pazopanib compared with placebo. In this review, we discuss the rationale and clinical evidence for the use of pazopanib in the treatment of metastatic and inoperable soft tissue sarcomas. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Netherlands | 1 | 4% |
Unknown | 23 | 96% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 5 | 21% |
Student > Bachelor | 3 | 13% |
Other | 3 | 13% |
Student > Doctoral Student | 2 | 8% |
Student > Postgraduate | 2 | 8% |
Other | 5 | 21% |
Unknown | 4 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 13 | 54% |
Business, Management and Accounting | 1 | 4% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
Agricultural and Biological Sciences | 1 | 4% |
Neuroscience | 1 | 4% |
Other | 0 | 0% |
Unknown | 7 | 29% |